Specifically, inhibition of METTL3 diminished the m6A modification of MALAT1, subsequently downregulated the MALAT1 expression to suppress EMT in BC by sponging miR-26b to reduce the expression of HMGA2 (Zhao et al., 2021). Here, HMGA2 is linked to breast cancer.